| Long-term Results of Reduced-fluence Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy. |
|
Ji Yun Han, Seong Woo Kim, Jaeryung Oh |
|
Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea. ksw64723@korea.ac.kr |
| 결절맥락막혈관병증에서 광역학요법과 항혈관내피세포성장인자 주입술 병합치료의 장기추적 관찰결과 |
|
한지윤⋅김성우⋅오재령 |
|
고려대학교 의과대학 안과학교실 |
Correspondence:
Seong-Woo Kim, MD, PhD
Email: ksw64723@korea.ac.kr |
|
Received: 26 January 2017 • Revised: 24 April 2017 • Accepted: 20 May 2017 |
| Abstract |
PURPOSE
To evaluate the long-term effects of reduced-fluence photodynamic therapy (RF-PDT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for polypoidal choroidal vasculopathy (PCV). METHODS: Twenty-two eyes of 21 patients with PCV that were followed up for more than 24 months after RF-PDT and anti-VEGF combination therapy were retrospectively reviewed. The patients received intravitreal anti-VEGF (bevacizumab 1.25 mg, ranibizumab 0.5 mg, or aflibercept 2.0 mg) within 7 days of PDT. Patients were retreated with either RF-PDT and anti-VEGF injection, or with only anti-VEGF injection, as indicated. The main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT), which were measured before and after combination therapy. RESULTS: During follow-up, the mean logMAR BCVA significantly improved from 0.75 at baseline to 0.54 at 12 months and 0.52 at 24 months (p=0.009 and p=0.032, respectively). The mean CFT significantly decreased from 409.8 µm at baseline to 234.1 µm at 12 months and 245.9 µm at 24 months (p<0.001 and p=0.001, respectively). In 20 eyes (90.9%), the BCVA remained stable or improved. CONCLUSIONS: The efficacy of this combination therapy for 24 months resulted in stabilized vision and anatomical improvement. RF-PDT combined with intravitreal anti-VEGF injection could be an effective treatment modality for patients with PCV. |
| Key Words:
Polypoidal choroidal vasculopathy;Reduced fluence photodynamic therapy;Vascular endothelial growth factor |
|
PDF Links
Full text via DOI
Download Citation
